Sun Pharma Advanced Research Company surged for a second straight session after a U.S. court ruled in its favour on the Sezaby Priority Review Voucher. The stock jumped over 11%, extending Tuesday’s 20% rally, even as analysts caution about overbought technicals and continued quarterly losses.Read More

Market expert Mayuresh Joshi advocates for selective investments in banking, infrastructure, and paint sectors. He favors ICICI Bank, SBI, and Bank of Maharashtra, while seeing potential in cement players as proxies for infrastructure growth. Joshi also recommends holding Asian Paints due to strong fundamentals and market expansion opportunities.Read More

The Indian rupee weakened past the 90-per-dollar mark for the first time ever, reaching ₹90.13 on Wednesday — a new record low. This follows five straight days of decline, despite efforts by the Reserve Bank of India to intervene. The fall reflects ongoing weakness in capital inflows, strong demand from importers, and uncertainty over a...Read More

Apis India announces a 24:1 bonus issue on 5th December as the stock hits its 5% upper circuit amid strong 12-month and five-year returns. The company reported a 5.5% YoY rise in quarterly net profit.Read More

Market outlook turns favourable for PSBs, with analysts seeing stronger upside than private banks ahead of the RBI policy. Anand Rathi’s Narendra Solanki prefers Aptus Value Housing in housing finance, Union Bank and Indian Bank among PSBs, and Vishal Mega Mart over Trent in retail. Here’s the full breakdown of his sector strategy and stock...Read More

AU Small Finance Bank leads the Nifty Bank with 64% returns, boosted by RBI’s in-principle nod for universal bank status. Analysts see it as a tech play and long-term bet, with mutual funds increasing their stake. The stock shows a bullish trend, with potential for further upside.Read More

Indian equities opened lower on Wednesday, extending a three-session slide as investors adopted a cautious stance near record highs. Both the Sensex and Nifty edged down, with market sentiment guarded ahead of the Reserve Bank of India’s interest-rate decision and policy cues due Friday.Read More

Sun Pharma’s subsidiary will invest Rs 3,000 crore in a new manufacturing facility in Madhya Pradesh. The company also launched its innovative drug Ilumya® in India. Despite a premium valuation, technical indicators suggest a generally bullish trend for the stock.Read More

The Indian rupee has fallen below the significant 90 mark against the U.S. dollar. This marks a continuation of its recent struggles. Weak trade and investment flows are contributing factors. Concerns about a stalled trade deal with Washington are also weighing on the currency. The rupee reached a new all-time low on Wednesday.Read More

Despite India’s strong 8.2% GDP growth, markets showed muted reaction as optimism was largely priced in. Geopolitical tensions and trade uncertainties are keeping investors cautious, while a weaker rupee benefits exporters but poses inflation risks. Infrastructure, pharma, and IT services are identified as key sectors to watch.Read More